Abstract:Objectives Diabetes-induced impairment of collateral formation in ischaemic myocardium has been demonstrated both in experimental and clinical studies, which may contribute to unfavorableprognosis among diabetic individuals. However, the underlying mechanism remains to be defined. Endothelial cell (EC) is thought to be one of the important elements in the development and maturation of coronary collaterals. Since ERK5 is a novel regulator of angiogenesis and closely related with VEGF, in present study we aim to determine whether ERK5 exerts a causative effect on advanced glycation end products (AGEs)-induced impairment of angiogenic capacity in cardiac ECs under hypoxia condition, and to identify the down streamtarget molecule. Methods Cardiac ECs were isolated from left ventricle of Sprague-Dawley rats with a enzyme digestion procedure described in our previous publications. Cells were treated with or without AGEs and then exposed to hypoxia or normoxia. Proliferation, migration and tube-forming of endothelial cells were detected by MTT, Transwell and Matrigel assay respectively. Protein of interest were further validated using ELISA and Western-blot techniques. Results Hypoxia promoted proliferation, migration and tube-forming capacity in cardiac ECs, which was inhibited significantly by combined administration of AGEs. Incubation with AGEs induced decrease of VEGF secretion and increase of ERK5 phosphorylation after hypoxia stimulation. XMD8-92, a inhibitor of ERK5 phosphorylation, treatment caused elevation of VEGF secretion, and counteracted AGEs-induced impairment of angiogenic capacity in cardiac ECs under hypoxia condition, which has a similar effect with supplementation of exogenous VEGF. Conclusions Our study demonstrated for the first time that hypoxia-induced enhancement of angiogenic capacity in cardiac ECs was inhibited in the presence of AGEs, which was related with downregulation of VEGF expression caused by ERK5 phosphorylation. Thus ERK5 may function as an important regulator in diabetes-induced impairment of angiogenesis and thereby exacerbated myocardial ischaemic injury through coordinately targeting VEGF in cardiac ECs. Intervention of ERK5 pathway mayrepresent an avenue for therapeutic exploitation to improve prognosis in diabetic individuals with coronary artery disease.

Endothelial β-catenin upregulation and Y142 phosphorylation drive diabetic angiogenesis via upregulating KDR/HDAC9

Autophagy protects against senescence and apoptosis via the RAS-mitochondria in high-glucose-induced endothelial cells.

Advanced glycation end products induce endothelial hyperpermeability via β-catenin phosphorylation and subsequent up-regulation of ADAM10

Involvement of Advanced Glycation End Products in the Pathogenesis of Diabetic Retinopathy

A Novel Angiogenesis Role of GLP-1(32-36) to Rescue Diabetic Ischemic Lower Limbs Via GLP-1R-Dependent Glycolysis

GW24-e3729 ERK5 Mediates Advanced Glycation End Products-Induced Impairment of Angiogenic Capacity in Cardiac Endothelial Cells under Hypoxia Condition Through Regulation of VEGF Expression

Advanced glycation end products activate Smad signaling via TGF- -dependent and -independent mechanisms: implications for diabetic renal and vascular disease

High-glucose Induced HIF-1α Down-Regulation Impairs the Function of the Endothelial Progenitor Cells Via PI3K/AKT Signaling Pathway

Angiopoietin-1 Protects the Endothelial Cells Against Advanced Glycation End Product Injury by Strengthening Cell Junctions and Inhibiting Cell Apoptosis

Endothelial Cell Senescence Contributes to Pathological Retinal Angiogenesis

Mechanistic Pathogenesis of Endothelial Dysfunction in Diabetic Nephropathy and Retinopathy

Exogenous Advanced Glycosylation End Products Induce Diabetes-Like Vascular Dysfunction in Normal Rats: a Factor in Diabetic Retinopathy

Diabetic Endothelium Dysfunction, Cardiovascular Complications, and Therapeutics

Glycation of Tie-2 Inhibits Angiopoietin-1 Signaling Activation and Angiopoietin-1-Induced Angiogenesis

Nrf2 transcriptional upregulation of IDH2 to tune mitochondrial dynamics and rescue angiogenic function of diabetic EPCs

Endothelial Progenitor Cells (epcs) Mobilized and Activated by Neurotrophic Factors May Contribute to Pathologic Neovascularization in Diabetic Retinopathy.

Endothelial Adenosine A2a Receptor-Mediated Glycolysis is Essential for Pathological Retinal Angiogenesis.

YAP/TAZ Signaling Enhances Angiogenesis of Retinal Microvascular Endothelial Cells in a High-Glucose Environment

Circ-ADAM9 Targeting PTEN and ATG7 Promotes Autophagy and Apoptosis of Diabetic Endothelial Progenitor Cells by Sponging Mir-20A-5p.

Activation of the Wnt Pathway Plays a Pathogenic Role in Diabetic Retinopathy in Humans and Animal Models.

The contribution of adiponectin to diabetic retinopathy progression: Association with the AGEs-RAGE pathway